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INTRODUCTION 
 Although uterine bleeding is a normal physiologic episodic occurrence 
for most women, its characteristics nevertheless vary considerably. The broad 
range of normal variation causes difficulty in identifying abnormal patterns. The 
problem is that uterine bleeding has a wide range of diagnostic possibilities and 
confusion is generated when review and reports fail to outline the diagnostic 
evaluation of the patient who presents with abnormal uterine bleeding patterns.  
            Goals of clinical management are primarily dependent upon attaining a 
correct etiological diagnosis. The history, physical and pelvic examination 
attempt to determine the site of the bleeding and its source. Information 
gathered from this will suggest what direction the investigation would take. 
Traditionally , Dilatation and Curettage and Ultrasonography were the most  
common investigations employed in the evaluation of the causes of abnormal 
uterine bleeding
1
.  
            Dilatation and Curettage is a blind procedure and the endometrium has 
to be sent to the Pathologist to study histological patterns and for the report. The 
co-operation of the Pathologist is important. Ultrasonography clearly depicts the 
uterine contour and the status of the ovary, but fails to provide adequate 
information regarding the endometrium.  
 Hysteroscopy has ushered a new era in the evaluation of abnormal uterine 
bleeding. By direct visualization of the uterine cavity , it is possible  to pin point 
the etiology in the majority of the cases. It can accurately detect endometrial 
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hyperplasia and aids in the early diagnosis of endometrial carcinoma and uterine 
polyps.  
 Abnormal uterine bleeding is one of the most common complaints with 
which a patient presents to a Gynaecologist. D&C has long been the diagnostic 
gold standard for abnormal uterine bleeding. However only 70% - 80% of the 
endometrium can be curetted. Polyps and sub mucous fibroids are frequently 
undetected by curettage alone
1
.  
            The judicious use of hysteroscopy to manage this medical entity adds a 
new dimension in handling this often perplexing problem.  
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AIMS AND OBJECTIVES 
 
 This study has been taken up to analyze the place of hysteroscopy in the 
evaluation of Abnormal Uterine Bleeding in terms of accuracy of hysteroscopic 
findings and the contribution of the procedure to clinical diagnosis. It also aims 
to correlate hysteroscopic findings with histopathological results. 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW:  
 “A vigilant eye in the uterine cavity is better than numerous blind 
curettages”, quoted Lindmann
2
, about the future of hysteroscopy. Observation 
ranks with percussion, auscultation and palpation as one of the principal 
methods of clinical examination. For this reason, physicians sought a simple 
method to look into the cavities of the human body. Until the beginning of the 
20
th
century, this possibility existed only for external orifices. 
 Archigenesof Apameia already had a grasp of illumination procedures, 
“et hoc ad claremlucemsiat.” Subsequently anal and vaginal specula were 
developed from simple tubes to more complex instruments for dilatation and 
observation. Various methods were devised using systems of concave mirrors 
and lenses, to collect and focus light from natural and artificial sources and 
direct it into a cavity
2
.  
 History of endoscopy really begins in the early years of the 19
th
century. 
In 1805, Bozzini(1773-1809) constructed a device called a light conductor that 
enabled him to inspect various passages and body cavities. In 1864, 
Aubinaisobserved a baby’s head emerge from the cervix with a tube he inserted 
into the vagina, and for this reason he has been described incorrectly as the first 
hysteroscopist.  
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 The first hysteroscopy (also called as metroscopy or uteroscopy) was 
described in 1869 by Pantaleoni
3
. Polypoid endometrial growths were observed 
by him. Pantaleoni used reflected candle from a concave mirror to illuminate the 
uterine cavity. In 1893, Morris
2 
used a straight silver and brass tube. He 
observed tubal ostia and endometrium. Bleeding and mucous obstructed his 
vision. So a new type of hysteroscopy was proposed by Beutner
5 
in 1898 which 
was equipped with water sprinkler . 
In 1907, David demonstrated the first contact hysteroscopy, which was useful 
for diagnosis of uterine disorders. In 1914, Heineberg
6 
devised a system for 
irrigating the uterine cavity to rinse off the blood that often covered the lens and 
hindered the lesion. In 1925, Rubin
7 
insufflated the uterine cavity with CO
2 
instead of water. In 1927, Mikulicz-Radeckiand Freund
2 
collaborated to 
produce a ‘curettoscope’ with biopsy taking capability and cornual electro 
coagulation.  
 In 1928, Gauss
8 
succeeded in taking intrauterine photography. In 1934, 
Schroeder collected important data on the intrauterine pressure during 
hysteroscopy. He succeeded in developing an instrument with an excellent 
forward viewing optical system. It thus became possible to inspect large areas of 
the cavity and to observe three-dimensional views.  
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 Other pioneers of hysteroscopy during these years (1934-1943) were 
Bank, Schackand Segond
9
. Norment
10 
in 1943 reported a new technique that 
called for transparent rubber balloon mounted on the tip of hysteroscope and 
illumination provided by an external light. Mohri
11 
and colleagues (1953-1978) 
reported on the possibility of embryoscopy and also introduced the first 
tubaloscope.  
 Englund
12 
and colleagues recommended hysteroscopy for uterine 
bleeding in 1957. In 1962, Sinander studied endometrial carcinoma using 
silastic balloon. A new era in hysteroscopy began with the introduction of 
viscous fluid as media for distending the uterine cavity. Menken
13 
in 1968 used 
Loviscol, a poly-vinyl pyrrolidine as distension media. Edstrom and 
Fernstromused Dextran (32%); Lindemann
14 
used CO
2 
as distending media in 
1972. In 1979, Nitze4 demonstrated a cystoscope with distal illumination, thus 
the present era in endoscopy began. The Nitze principleof endoscopy was not 
adopted for hysteroscopy . 
 In 1979 Baggish
15 
reported his first experience with contact hysteroscope. 
In 1981, Hamou
16 
demonstrated microhysteroscope, modern panoramic 
hysteroscopy with a variation of contact hysteroscopy in a single endoscope. 
Panoramic hysteroscope and all channel operating sheath was described 
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byBaggishin 1987. Recently Baggish also developed a special dual channel 
hysteroscope for intrauterine laser surgery
17
.  
 Hysteroscopic operative removal of myoma has been advocated as a more 
efficacious and safe procedure. Recently most hysteroscopic surgeons have 
preferred to perform myomectomy utilizing Hyskon as the distending medium, 
because of its lack of miscibility with blood and optical clarity. Although no 
hysteroscopic method of tubal occlusion can be accepted as practical at present, 
it seems reasonable to accept that the hysteroscopic approach remains 
promising.  
 The future of hysteroscopy is assured. The day is not far off when this 
procedure will occupy the same pre-eminent position in Gynecology as 
cystoscopy holds in Urology.  
 Siegler
18
in 1976 studied 257 cases of AUB with hysteroscopy and 
reported that 41.7% patients had normal endometrium and 58.3% had abnormal 
endometrium. Sciarraand Valle
19 
in 1977 reported on 320 cases of AUB and 
returned with 28.8% normal endometrium and 71.2% abnormal endometrium. 
Barbot
20 
in 1980 reported 84% accuracy in his series. Baggish
15 
in 1979 
reported 47.1% normal endometrium and an accuracy of 87.5% in his series of 
hysteroscopy in AUB. 
 Valle
21 
in 1981 studied 419 pre-menopausal and 134 post-menopausal 
patients who had abnormal uterine bleeding. Hysteroscopy was performed prior 
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to D&C. In 352 pts an abnormality on hysteroscopy was detected, such as 
endometrial polyps, submucousleiomyomas, and intra-uterine adhesions. He 
concluded that hysteroscopy provides a precise and accurate adjunct to 
traditional methods of diagnosing intra-uterine abnormalities, particularly focal 
lesions missed at curettage.  
 Gimpelson
22 
in 1984 studied 66 women who underwent panoramic 
hysteroscopy prior to D&C. In 51 of these pts, a directed biopsy was performed 
through the hysteroscope. In 48 cases the results of hysteroscopy and curettage 
were in agreement. Hysteroscopy revealed more information than curettage in 
16 pts, whereas curettage revealed more information than hysteroscopy in only 
2 pts.  
 Wamsteker
23 
in 1984 analyzed 199 patients of AUB with hysteroscopy. 
He used Hyskon as distension medium. In 85 patients (41.5%), no abnormality 
was seen. 20 pts had atrophic endometrium, intra-uterine tumors were found in 
67 cases and endometrial hyperplasia in 25 pts. In his opinion, hysteroscopy is 
indispensable for the diagnosis of intrauterine tumors in women with AUB. In 
case there is an intrauterine pathology, histological examination is always 
necessary to evaluate the hysteroscopic diagnosis.  
 Gimpelsonand Rappold
24 
in 1988 studied a total of 276 women who 
underwent both hysteroscopy and D&C. In 223 cases the results of 
hysteroscopy and curettage were in agreement. Hysteroscopy revealed more 
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information than curettage in 44 pts, whereas curettage revealed more 
information than hysteroscopy in only 9 pts. When he compared the results of 
this study with his previous study, there was little doubt that panoramic 
hysteroscopy is superior to curettage in making an accurate diagnosis of 
pathologic conditions in the uterine cavity. 
 Loffer
25 
in 1989 evaluated 187 patients with abnormal uterine bleeding. 
Hysteroscopy was more accurate in 9.1% and less accurate in only 0.5% of 
patients. The specificity of both techniques was 100%, but the sensitivity of 
hysteroscopy was greater (98%) than that of D&C (65%). Endometritis was the 
only condition missed by hysteroscopy. The lesions missed by D&C were 
uterine fibroids and polyps. Among 91 pts the hysteroscopic view was negative. 
 Seth
26 
in 1990 evaluated the role of hysteroscopy in 51 pts. Abnormal 
findings were noted in 56% of cases. Intrauterine myomas and polyps were 
diagnosed with greater accuracy (81.8%) than histological abnormality of the 
endometrium (71.4% accuracy). The overall accuracy of hysteroscopic findings 
in abnormal uterine bleeding was 92%. The procedure changed the clinical 
diagnosis in 21% pts, confirmed it in 66% and either failed or was proven 
inaccurate in the remaining 13% of cases.  
 Parasnisand Parulekar
27 
in 1992, reported on 96 cases of AUB 
evaluated by both hysteroscopy and D&C. 76% of the patients had normal 
endometrium. Hysteroscopy diagnosed endometrial polyp and submucous 
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leiomyoma with 100% accuracy. In 17 cases the results of hysteroscopy and 
curettage were in agreement. Among the 73 cases with negative hysteroscopic 
view, an abnormality was detected by tissue sampling in only 2 patients. The 
accuracy of hysteroscopy (92%) was greater than curettage (76%). He 
concluded that hysteroscopy may prove to be superior to curettage in making an 
accurate diagnosis of intra-uterine pathology.  
 Neumann and Astudillo
28 
in 1994 compared the results of hysteroscopy 
and D&C performed in 85 pts. In 47 pts (55.2%) the hysteroscopic diagnosis 
was normal, in 16 pts (18.8%) was hyperplasia, in 17 pts (20%) was polyp, 4 
cases (4.7%) were described as cancer and in 1 case (1.3%) the diagnosis was 
bone metaplasia. He obtained a correlation of 93%.  
 Liu and Zhou
29 
in1995 compared the results of 124 cases of AUB 
examined with hysteroscopy with pathological findings obtained during 
curettage. Hysteroscopy and D&C agreed on the diagnosis in 92.7% pts. There 
were 9 cases misdiagnosed by hysteroscopy and 6 cases had false negative 
results during curettage. Hysteroscopy is an effective method for identifying the 
causes of postmenopausal bleeding, which is superior to curettage of uterus.  
 Naegle
30 
in 1996 conducted a comparative observational study to 
determine the role of out-patient diagnostic hysteroscopy in patients with AUB 
on HRT and to contrast this with a central group of women presenting with 
post-menopausal bleeding. He concluded that there was a high incidence of 
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intra-uterine abnormalities in women with menstrual symptoms while taking 
HRT, but the pathology differed from those with post-menopausal bleeding. As 
focal lesions are found commonly in such patients, their detection by diagnostic 
hysteroscopy should improve compliance with HRT as it will allow 
individualization of treatment.  
 Loverro et al
31 
in 1996 studied 980 women with abnormal uterine 
bleeding with hysteroscopy and D&C. Positive predictive value of hysteroscopy 
in the diagnosis of endometrial hyperplasia was 63%. Sensitivity and specificity 
of hysteroscopy was 98% and 95% respectively. Negative predictive value was 
99%. PPV was higher in postmenopausal women compared to women in the 
fertile age (72% v/s 58%)  
 Torrejon et al
32 
in 1997 studied 1398 pts of AUB with hysteroscopy and 
D&C. Endometrial hyperplasia was diagnosed with an accuracy of 92.5% in 
premenopausal and 97.3% in postmenopausal women. Adenocarcinoma was 
diagnosed with an accuracy of 99.5% in premenopausal and postmenopausal 
women.  
 Panda and Parulekar
33 
in 1999 studied 66 pts of AUB with hysteroscopy 
and D&C. They were in the age group of 25-70 years. Abnormal findings were 
detected in 53.5% of cases. Hyperplasia was the commonest finding. The 
sensitivity of hysteroscopy was 92.5% and that of D&C was 83.3%. False 
   12
negative value of hysteroscopy was very low. The negative predictive value was 
93%.  
 Trotsenburgand Nagele
34 
in 2000 evaluated the feasibility and diagnostic 
accuracy of out-patient diagnostic hysteroscopy in pre menopausal patients 
suffering from AUB. Intra-uterine pathology was diagnostic in 34% patients, 
the most frequent being submucousmyomas and endometrial polyps. He 
concluded that diagnostic hysteroscopy is a simple and safe technique, well 
accepted by majority of patients with an excellent diagnostic accuracy and with 
a high success rate as an out-patient procedure.  
 Garutiet al
35 
in 2001 conducted a study to estimate the accuracy of 
hysteroscopy in predicting endometrial histopathology. 1500 women with AUB 
were studied. Hysteroscopy showed sensitivity, specificity, NPV, and PPV of 
94.2%, 88.8%, 96.3%, and 83.1% respectively. Highest accuracy was in 
diagnosing endometrial polyps, with sensitivity of 95.3%, specificity 95.4%, 
PPV 98.9% and NPV 81.7%.  
 Madanand Al-Jufairi
36 
in 2001 retrospectively studied 556 cases of 
AUB, who underwent hysteroscopy and D&C. 53, were diagnosed to have 
endometrial polyps hysteroscopically, however only 13 pts were confirmed to 
have polyps histologically. Hysteroscopy was highly specific for diagnosis of 
both endometrial hyperplasia (85%) and endometrial carcinoma (99.5%); 
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however the sensitivity of hysteroscopy for diagnosing endometrial cancer was 
40% and 30% for endometrial hyperplasia.  
 Clark
37 
in 2002 conducted study on the accuracy of hysteroscopy in the 
diagnosis of endometrial cancer and hyperplasia. They concluded that 
diagnostic accuracy of hysteroscopy is high for endometrial cancer, but only 
moderate for endometrial diseases.  
 Bain
38 
in 2002 evaluated and compared the clinical benefit of additional 
out-patient hysteroscopy over traditional vaginal examination and endometrial 
biopsy in unselected pre-menopausal women and 370 women were recruited in 
the study and he concluded that out-patient diagnostic hysteroscopy is an 
acceptable procedure and may give more reassurances. It does not influence 
clinical management, especially with respect to hysterectomy rate. Out-patient 
hysteroscopy may be useful in selected cases, but when performed in a non-
selective manner, it has little influence on clinical management and increases 
costs.  
 Gianninoto
39 
in 2003 conducted a retrospective study of diagnostic 
hysteroscopy in AUB and concluded that ambulatory hysteroscopy was shown 
to be a simple, safe, well tolerated and reliable procedure in the diagnosis of 
AUB across all age-groups and its wide spread use can drastically reduce the 
need for conventional curettage, thereby increasing patient satisfaction and 
lowering costs.  
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 deWitand Vleugels
40 
in 2003 evaluated 1045 hysteroscopies performed 
over 6 years retrospectively. Normal cavity was found in 54.2%. Most common 
abnormal findings were fibroids (21%) and endometrial polyps (14.4%). 
Hysteroscopically diagnosed hyperplasia of the endometrium was confirmed in 
only less than half the cases. Endometrial carcinoma was suspected on 
hysteroscopic view in 2 cases of a total of 7 proven cases. Diagnostic 
hysteroscopy is a valuable tool in diagnosing structural intra-cavital pathology, 
very suitable for out-patient clinic. 
PHYSIOLOGY OF MENSTRUATION 
 Menstruation is a veryrecent  phenomenon intheevolutionary  time  line. 
It occurs invery few species. Thediagnosisand management of abnormal  
menstrualfunctionmust be based on an understanding of the physiologic  
mechanismsinvolved in the regulation of the normal cycles.  Although the   
activity of the endometrium is directlycontrolled by the ovarianfunction and by 
the two hormones secreted by the ovary, the ovaryitself is activated by the  
pituitary   gland,  the  secretion   of which  is  under  the   nervous   control   of   
the hypothalamus. 
 The normal human menstrual cycle can bedivided into two segments: the  
ovariancycleand the uterine cycle, basedon the organ under examination. The 
ovarian cycle may be further divided into follicular and luteal phases, 
whereasthe uterine cycle is divided into the corresponding proliferative 
andsecretory phases.           
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 At   the   beginning   of  each  monthly  menstrual  cycle,  levels of 
gonadal   steroids   are   low  and  have  been  decreasing  since  the  end   of   
the  luteal  phase  of   the   previous  cycle. Withthe demise of the corpusluteum, 
FSH levels begin to rise and acohort of growing follicles is recruited. These 
follicles each secreteincreasing levels ofoestrogen as they grow in the follicular 
phase. Thisin turn, is the stimulus for uterine endometrial proliferation. 
 Rising  oestrogenlevels   provide   a  negative  feedback  on  pituitary 
FSH  secretion which   begins   to   wane   by   the   midpoint   of   the follicular   
phase.  Conversely,   LH   initially   decreases   in   response  to rising   estradiol   
levels  but   late   in the follicular phase the LH level is increased   dramatically  
(biphasic response). At the end of the follicularphase (just prior to ovulation), 
FSH inducedLH receptors are present ongranulosa cells andwith LH 
stimulation,modulate the release of Progesterone. 
 After    a    sufficient    degree   of   oestrogenic   stimulation,  the 
pituitary    LH    surge   is   triggered,   which    is   the   proximate   cause of  
ovulation   which  occurs   24-36   hours   later.  Ovulation  heralds the   
transition   to   luteal secretory  phase.  The oestrogen  level decreases   through   
the   early   luteal   phase   from  just   before   ovulation  until  the   midluteal 
phase  when   it   begins   to  rise  again as   a    result  of   corpus   
luteumsecretion.   Progesterone   levels  rise precipitously   after   ovulation  and  
can  be used  as  a   presumptive sign   that ovulation  has occurred  .   Both 
oestrogen   and   progesterone   levels   remain   elevated    throughout   the  life  
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of  the    corpus    luteum and    then   wane   with   its    demise,   thereby  
setting the   stage   for   the   next   cycle. 
 In  the   absence   of   implantation,  glandular   secretion  ceases  and  an   
irregular   breakdown  of   the   decidua   functionalisoccurs. The result   is   a  
shedding  of   this  layer  of   the endometrium ,  a  process termed   menses. 
 A   normal   menstrual   cycle   lasts  from  21   to  35    days  with  2 to6  
days  of   flow  and an  average   blood   loss  of  20-60ml.However studies of 
large numbers ofwomen with normal menstrual cycles  haveshown that only 
approximately two- thirds of adult women have cycles  lasting  21-35 days . The 
extremes of reproductive life  arecharacterizedby a higher 
percentageofanovulatory or irregularly timed cycles . 
ABNORMAL UTERINE BLEEDING 
 Abnormal  uterinebleeding  is   a   common  clinical  problem  with  
myriad  of   causes. A   solid   knowledge   of   menstrual  physiology and    
athorough   approach   to   differential    diagnosis can assist  the 
gynaecologistevaluate and manage the problem with confidence. 
Terminology Used to Describe Abnormal Uterine Bleeding52 
Menorrhagia :  Prolonged  or  excessive  bleeding  at   regular  intervals.  
Metrorrhagia :  A  period  of  menstrual  bleeding longer than 7 days or   
interval  bleeding.  
Menometrorrhagia : Prolonged  or  excessive  bleeding  at  irregular intervals.  
Polymenorrhoea :  Regular  bleeding  at  intervals  of  less  than  21 days. .  
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Oligomenorrhoea :Bleeding  at   intervals   greater   than   every   37 days.  
Amenorrhoea :absence of menstruation  for   at   least   6   months.  
Intermenstrual :  bleeding   between  regular   cycles.  
Post menopausal bleeding :   bleeding   occurring   more   than 12   months   
after   the   last   menstrual   period   of   a   menopausal women.  
EVALUATION OF AUB 
History taking:  
 The    specifics   of   the   bleeding   pattern   should   be elicited   on   
history   taking. The    frequency, duration,   and   severity of flow    should   be   
ascertained. It     is also   critical   to   determine if   the bleeding   is   acyclic   
or    cyclic,   the   latter   being   more consistent with ovulation. Other    
important    considerations include patient age, sexual    history (which   
determines   risk    for   sexually   transmitted   diseases),   previous    
gynecologic   disease,   likelihood   of   pregnancy,  use   of     medications   or   
hormonal   contraceptives,  and   the   presence    of    chronic   medical   
problems1.  
Physical Examination:  
 Evidence   of   systemic   disease   should   be   sought   on   physical     
examination. Signs   and   symptoms   of   hypothyroidism, liver   disease,   
hyperprolactinemia, eating   disorders, and   coagulopathies   warrant   special   
attention. A   thorough   pelvic examination,   including   a   Pap  smear, is   
essential. If   indicated  by history   or   physical   findings, cervical   cultures   
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y FIGO Menstrual Disorders Group  (FMDG) 
y Stratified into 9 basic categories acc. to the acronym 
Anovulatory Bleeding56:  
 Anovulation is themost common cause of DUB in reproductive-age 
women and is especially common in adolescents. Upto 80 percent of menstrual 
cycles areanovulatory in the first year after menarche. Cycles become 
ovulatoryon an average of 20 months after menarche. If anovulatory bleeding is 
notheavy or prolonged, no treatmentis necessary. If the adolescent is distressed 
by the irregularity of    her menses or has beenanovulatory for more than a year, 
oral contraceptive pills are the treatment of choice55. 
.  All causes of anovulation represent a progesterone-deficient state. 
Treatment options include exogenous progesterone everythree months    to    
protect     against     endometrial   cancer, oral   contraceptives or, if   pregnancy   
is    desired, ovulation   induction   with   clomiphene. 
Ovulatory Dysfunctional Bleeding: 
 Although   less   common   than   anovulatory   bleeding, ovulatory   DUB   
may   also   occur. DUB   in   women   with   ovulatory   cycles occurs   as   
regular, cyclic    bleeding. Menorrhagia   may   signify   a   bleeding disorder   
or   a   structural   lesion, such   as   uterine leiomyomas, adenomyosisor  
endometrial   polyps. Up    to   20   percent   of  adolescents who present with 
menorrhagia have a bleedingdisorder such as vonWillebrand's disease. Liver 
disease with resultant coagulation abnormalities and chronic renal failure may 
also cause menorrhagia.  
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Characteristics of Ovulatory and Anovulatorycycles55 : 
Ovulatory cycles  
1. Regular cycle length  
2. Presence of premenstrual symptoms 
3. dysmenorrhoea 
4. Breast tenderness  
5. Change in cervical mucus  
6. Mittleschmertz 
7. Biphasic temperature curve  
Anovulatory cycles  
1. Unpredictable cycle length  
2. Unpredictable bleeding pattern  
3. Frequent spotting  
4. Infrequent heavy bleeding  
5. Monophasic temperature curve  
 
PERIMENOPAUSAL WOMEN 
 As   women   approach   menopause,   cycles  shorten and often   become   
intermittentlyanovulatory. These changes are the result of a decline in the 
number of ovarian follicles and in theestradiol level. Asfolliclesdecrease in 
number, the level of follicle-stimulating hormoneneeded to stimulate ovulation 
increases.  
Excluding Endometrial Carcinoma56:  
 Allperimenopausal women with persistent abnormal uterinebleeding 
should be evaluated for the presenceof endometrialhyperplasia or carcinoma. 
Endometrial biopsy is the most widely used and best studied method of 
excluding endometrial carcinoma in this age group. Inwomen with 
normalfindings on biopsy, treatment usually consists of monthly progesterone 
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withdrawal or low-dose oral contraceptives. If bleeding continues despite 
hormonal therapy, further investigation is warranted  
POSTMENOPAUSAL WOMEN 
 The   most    serious   concern    in    postmenopausal women with 
abnormal   uterine   bleeding   is    endometrial   carcinoma. Of   all 
postmenopausal   women    with   bleeding,   5 to 10   percent   are   found   to 
have endometrial   carcinoma. Other    potential   causes   of    bleeding    are 
cervical    cancer,  cervicitis,  atrophic  vaginitis,  endometrial   atrophy, 
submucous  fibroids,  endometrial  hyperplasia  and  endometrial   polyps56.  
Hormone Replacement Therapy: 
 Women receiving hormone replacement therapy often   presents 
withabnormal    bleeding and, ofthese, 30 percent have uterine pathology. Other 
causes includecervical lesions, vaginal pathology or the hormone therapy itself. 
Women receiving sequentialhormone replacement therapy may 
experiencemidcyclebreakthrough bleed resulting from missed pills, medication 
interactions ormalabsorption. If unscheduledbleeding occurs in   two   or more 
cycles,   further   evaluation   is    indicated56.  
Treatment options for Dysfunctional Uterine Bleeding54 
Premenopausal:  
¾ Oral contraceptives: Low dose (35mcg) monophasic ortriphasic oral 
contraceptives can regulate cycles while providing contraception.  
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¾ Medroxyprogesterone: (10mg/dayfor 10 days) If contraception is not an 
issue, it can be used to regulate cycles. In a woman who 
hasamenorrhoeaoroligomenorrhoea,medroxyprogesterone every 3 months 
can protect against endometrial hyperplasia.  
¾ Clomiphene: (50-150mg/day on days 5 to 9) can induce ovulation in a 
woman who desires pregnancy.  
Perimenopausal:  
¾ Medroxyprogesterone: (10 mg per day for 10 days) May use monthly to 
regulate bleeding patterns.  
¾ Oral contraceptives :( 20-μg) Can continue oral contraceptives until a 
woman has finished menopause and then change to HRT. (May be a 
relative contraindication in women>35 years of age and who smoke)  
Postmenopausal (receiving HRT):  
¾ Cyclic HRT: Consider increasing the progesterone dose if early 
withdrawal bleeding occurs. Increase the oestrogendose if 
intermenstrualbleeding is present.  
¾ Continuous combined HRT: May increase theoestrogendose for 1 to 
3 months to stabilize the endometrium. May also try increasing the 
progesterone dose. If bleeding continues, consider changing regimen 
tocyclic HRT or using a different type of oestrogen.  
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HYSTEROSCOPE 
The   term  “hysteroscopy”  is  derived  from  the  fusion  of  two  
ancientgreek words“histeros” (uterus) and “scopeo” (to see) and refers to the 
“direct visual examination ofuterine cavity”.Indeed hysteroscopy is a procedure 
in which an illuminated scope called“hysteroscope”is inserted through the 
cervix into the uterine cavity that has beendistended by a fluidor gas 
distensionmedium, in order to diagnose or eventually treat  uterine 
abnormalities. Goodvisualization   is the keyto a correctdiagnosis and 
aprecisetreatment. The five essential elements for an optimal visualization 
include:Monitor,Endocamera, Light source, Lightcable  
 
and Optic. 
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ENDOCAMERA 
         In  modern  hysteroscopy  the  human  eye  has  been  replaced  by the  
endocamera  (Fig. 1).   Several  types  of  endocamera  are available,  each  
differing   from   the  other  in three  main characteristics: 
            • Sensibility 
            • Resolution 
 • Definition 
 
 Sensibility, measured  in lux,  represents  the  minimal  quantity  of    
light  necessary  to  make  captable  an  image;  resolution represents  the  
number  of  vertical  lines  which  constitute  the  image, which   can   be   
detected   on   the  screen; picture  definition  is proportional  to   the  number  
of   picture  elements,  called   pixels, produced   by   the   chip.  The   chip   is  a  
microprocessor  also  called Charged  Coupled  Device (CCD)  because it 
transformsthe real image into an electronic signal. The image captured by the 
endocamera is splitinto the three maincolours: red, green andblue, which are 
send either to one or to three   different   chips,  one   for    each   colour.  
Obviously,  the  higher  the  number  of  chips, the  better  is  the   chromatic   
accuracy   of   the   image . 
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LIGHT SOURCE : 
 In   1960   Karl   Storz   discovered   that   it   was  possible  to transmit 
light   from   a   light   source   outside   the   body  via  a  light  cable  through  
an  endoscope  to  the  examination  site.  This discovery markedthe  birth  of  
“cold  light  endoscopy”  . During the last 40 yearsseveral types of light sources 
each one morepowerful than the other have been developed inorder to provide a 
clear vision inside the uterinecavity which is characterized by a high absorption 
oflight, because of the predominance of redcolour.  
At present xenon light sources are preferred to the halogen ones forseveral 
reasons: 
• Produce   twice   the  light  output  as  a  modern  halogen lamp 
• Provide   white  light,  which   is   ideal   for   endoscopy 
• The   light   intensity   is   uniform  while   lamp   lasts 
• Have   a    longer  duration   (nearly 500 hours) 
• And    a    realer   colour   temperature   (6000 K)   which  results                                    
in    better  colour  chromatic  performance 
                 A   175   watt   xenon  light  source     gives  good  depth  of field,  
enough   to    perform  an   adequate   office    operative hysteroscopy. A    light   
source   of   300W   is  recommended   for video recording. 
LIGHT   CABLE  : 
 Two types of cables cantransmit thecold lightfrom    the light source to 
the endoscope. Thetransmissionoflight through a glass   fiber cable depends on 
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thephenomenon of total internal reflection. If a fiber isstraight or curved, light 
entering one end travels in azig-zag path, repeatedly reflecting off the 
internalsurface of the fiber until it emerges from the otherend, with the same 
angle of incidence of the entrance .  
 These    glass  fibers   are   rather  vulnerable:  damage  or  rupture   of   
these   fibers   caused   by   forced   bending   will  immediately  reduce   the  
light  intensity.  Theliquid  crystal cables  are  made  of  a  fluid  medium, 
typically  colesteric saline. These cables   transmit   a   higher   light  intensity  
for  a  similar  power of light  emission,  in  comparison with optical  fiber  
cables.  Despite their  higher  rigidity,  which  may  often  hamper  the   
endoscopic  procedures, it     has    the   distinctive  advantage   of   duration. 
OPTICS : 
 An   endoscope   is   an   optical   instrument   permitting visual     and    
photographic   examination   of   the   body   cavities   and internal    organs    
that   are   inaccessible   for   direct   viewing. Basically   an   endoscope   
consists   of   an   optical   system   to   carry   light   in   order   to   illuminate   
the  object    being  viewed  and  either  the   same   (as   in   contact   
hysteroscope)   or    generally   different   optical   mechanism   for   conveying  
the  image   back   to   the   eye   or  camera. The   image   may   be   conveyed   
through   a   series   of   lenses   in   which   case   the   endoscope   tube   is   
rigid   or   it   may  be   carried   to   the   viewer   by   means   of   light   trapped   
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Hopkins  lens-scope  based hysteroscopes),  once   the   tip   of   the   scope  is    
placed   1-1.5cm from    the   fundus,  permits   a   rapid   and   easy  evaluation  
of   all the   uterine  walls,  the  corneal   recesses   and   tubal ostia  by simply  
by  simply   rotating   the   telescope   slightly  on   its   axis   to   the right   or   
left.   On  the  contrary,   the    same  view  with   a  0 degreescope is possible 
only byangulating thewhole instrument to theleftorright bylateral movements 
thus determining amajorstretching ofcervicalmyometrial fiberswhich is mostly 
responsible for patient’s   discomfort .  In the early 90s, together with the  
development   of   rigid   hysteroscopes, improvements   in    fiberoptic    
technology  allowed    manufacturers  to create    0-degree   flexible   
hysteroscopes   characterized   by   a smaller   diameter   thus   less   
invasiveness   in   comparison   with   the rigid   ones. 
1. CONVENTIONAL PANORAMIC HYSTEROSCOPE 41  
 This is the most widely used method. The principle is simple involving 
visualization by means of a telescope of the uterine cavity using a liquid or a 
gaseous medium for distension. It has the following parts 
SHEATH:  
         Before    entering   the   uterine   cavity,   the   telescope   must  be fitted   
to   a   sheath  through   which   distending   medium   is   infused. To   provide   
reasonable   clearance   for   4mm   telescope, the diagnostic    sheath   measures   
5mm   in   outer   diameter. Entry   into the   interior   cavity   of   the   sheath   
is   provided   with   single stopcock   with   a   leur-lock   fitting. The   terminus  
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of   endoscope should   be   flush   with   the   sheath. It   is   made   up   of   
stainless steel    and   is   sterilized   like   an   obturator. It   is   27cm long.  The 
sleeve   has   an   inlet   and  outlet  for   liquid   medium   which   is   used    to     
distend   the   uterine   cavity. There   is   also   a  channel   for   operating   
instruments   near   proximal   end. The   sleeve   forms   a   channel   for    the   
passage   of   the   panoramic   hysteroscope. A cylindrical   collar   is    present   
on   the   shaft. It   can   be   slided forward   and   backward   and   can   be   
fixed    in   any   desired position   by   means   of   a   screw. The   distal   part   
of   the   sleeve   is graduated in centimeters. Position of the collar is    
determined by    utero-cervical   length. 
HYSTEROSCOPE:  
 The    optics   of   the    telescope   and   the   fibre   optic lighting   system    
is     as     in   a   laparoscope. Usually   there   is   a   30 degree   fore   oblique    
lens   which    permits    visualization  of   tubal    ostia   and   the   lateral   
uterine   walls   more   easily. The   telescope   has    3   parts   the   eye   piece,   
the   barrel   and   the  objective lens.  
CERVICAL CAP:  
 It    is   made   up   of   stainless   steel   and   is  7.5cm   long. Its one   
end   is   cup   shaped. The   cavity   of   the   cup   communicates with   a   tube   
which   runs   parallel   to   and   in   contact   with  the shaft   of    the   
instrument. A    two   way    valve   can   be    used   to close   off   the   lumen   
of   the   tubing. The   inner   diameter   of   the instrument   is   such   that   the   
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hysteroscope   sleeve   just   fits   in   its cervical   cap   and   prevents   leakage   
of   the   distending   medium.  
2. CONTACT HYSTEROSCOPE : 
 It    is   a   type   of   rigid   endoscope   and   among   all modern   
hysteroscopes   only   the   contact   hysteroscope   requires neither    a   sheath   
nor   a   distending   medium, available   just   for diagnostic    purposes. 
Theprinciple in this method is the objective lens is kept in contact with the 
structure under going scrutiny.  
 It   has   a   rod   lens, objective   eye   piece   that   is adjusted   for   sharp   
focus   on   an   object   at   the   distal   surface of the   lens. It   measures   
200mm   in   length   and   6-8mm   in width. Objects   to   be   viewed   are   in   
clearest   focus   when   in   actual contact   with   the   end   of   hysteroscope. 
One   significant   advantage of   the   contact   hysteroscope   is   it   squeezes   
blood    and   tissue fluids   away    from   the   object   to   be   viewed,   
providing   a   clear image.  There    is    very    little   distortion  of   the   image   
because  the angles   of   entry   and   exit   of   the   light  rays   are   identical   
and the   rays   are   transmitted   through  the   same   channel. 
MICROHYSTEROSCOPE : 
 It    is   the   most   sophisticated   and   is   the   latest technique. It    
measures   250mm   in   length   and   4mm   in   diameter with    wide   (90°)    
field   of   vision. The   distal   lens   is   sharply angulated   to    facilitate   
atraumatic   penetration   of    cervical   canal.  Double    ocular    setup    
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includes   push   button   selections   for panoramic   or   contact   mode   as   
well   as     for   various magnifications1. 
 Four    magnifications   x1, x20, x60 and xl50   are   described   by   
Hamou. The   x1   magnification   selection   is   similar   to panoramic   view   
offered   by   conventional   hysteroscope. At   x20 magnification   the   image   
is   similar   to   that   seen   in   colposcope with   appreciation   of   glandular   
and   vascular   structures   being possible.    At   x60  with  light   contact   with   
mucosa, previous   staining   will    aid   examination   of   glandular   
abnormalities. With direct   contact   at   x150  magnification,   
nucleocytoplasmic examination   of   cervical cells   is   possible. The   entire  
sheath   for diagnostic   purpose   is   5.2mm   and   contains   4mm   endoscope   
and   channel   for distending medium. An operating sheath witha 
maximumdiameterof 6.5mm is available with a 14mm channel for introducing 
flexible instrumentssuch as biopsy forceps,electroprobes, catheterandintratubal 
devices. 
4. PORTABLE OUT-PATIENT HYSTEROSCOPES  
The Yan De Pas Hysteroscope:  
 Yan  de  pas (1983) system   was   designed   for   single handed   
outpatient  use   and   consists    of   a  portio-adaptor   and 4mm   telescope   
with   a   30°  angle of   vision   and   70°   field   of vision. The  unique  feature  
of   the  instrument   is   sliding mechanism   operated    by   the  surgeon   single  
handedly   which enables   the  telescope   to   be   advanced   slowly   and    
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safely   into  uterine cavity  for  a  maximum  of  7cm,  therefore  reducing 
chances   of   perforating   fundus.  
The Parent self contained out-patient system:  
 This    hysteroscope   consists   of   a   4mm   lumina   telescope    in   a   
sheath  held   by   a   completely   self   contained  unit which    provides   both   
illumination   and    gas   for   distending  the uterine   cavity. Gaseous   
distension   is    provided    by    a    replaceable    cartridge    of   CO2   gas    at   
a   maximum   flow   rate   of 100 ml/min. The    gas   enters   the   uterus   from   
a   hole   in   the sheath   near   the   tip   of   the   telescope. Each    cartridge   
contains   4   litres   of   gas   under   pressure   which   allows   about   10 
hysteroscopies   or   a   flow   of   about   1   hour  20mts  at   a   flow rate of 
50ml/min. Illumination is provided by 3 rechargeable batteries placed in the 
handle of the unit. This light source is adequate for panoramic hysteroscopy. It 
is not bright enough for photography. Advantage of theparent system is that it is 
completely self contained and portable.  
SPECIALISED HYSTEROSCOPES  
The Flexible Hysteroscope:  
 All   hysteroscopes   so    far   considered   are   rigid. Flexible   
hysteroscopes   are   being   developed   and   may   provide some   advantages. 
The   flexible   instrument   is   a   modified choledochoscope    that   is    6mm   
in   diameter. The   telescope   with its    channel    for   gas   or    fluid   
insufflation   is    introduced   through the   cervix   after   minimal   dilatation   
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and    the   tip   can   be   angled through    180°    by    a    wheel   on   the   
proximal   end. Although   the view    is    grainier   than    a   rigid    telescope    
because   of   large number    of    fibres,   the   view    especially    at    cornua   
is   better than    that   provided   by   conventional   hysteroscopy   and   this   is   
an    advantage    for   the   insertion   of   intratubal   devices   for   tubal 
sterilization.  
The Hysteroser: 
 It    has   a   unique   telescope  consisting   of   a   rod   of optic   glass   
which   ends   in   a   concave   mirror. An   ingenious   and  unique  device  of   
mirrors   and   diaphragms   that    traps   and  concentrates  ambient   light   so  
that   no external   light   source   is required    for   illumination   being   
provided   by   day  light  or reflected  light   from  theatre   lamp. This   makes  
the unit completely   portable. It   can   be   only   used   as   contact 
hysteroscope. 
RIGID  CONTINUOUS FLOW HYSTEROSCOPES : 
 One    of    the   most   commonly   used   rigid   hysteroscopes  is  the   
Continuous  Flow   Hysteroscope   “size 5”  developed   by   Storz,  based on   a   
2.9 mm   rod lens    system    with   30-degree   foreoblique  view,  and   an   
outer  diameter  corresponding  to  5.0 mm. Recently, a thinner version has been 
developedbasedon a revolutionary2.0 mm rodlens system scope that reduces the 
final diameter of thehysteroscope to 4.0 mm. 
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DISTENSION   MEDIA  : 
 Theuseof mediais critical forpanoramic inspectionof the uterine cavity. 
Without media, the uterus is a narrow slit. Intrauterine pressures needed 
toadequately view the endometrium are proportional tothe muscle tone and 
thickness of the uterus. A pressure of 75 mm Hg isadequate for uterine 
distention. Rarely ismore than100 mm Hg required, and higher pressures can 
result in increased risk ofintravasationof media. The refractiveindex ofeach 
medium option affects magnification and visualization of the endometrium.  
 Media leakage can occur throughthe cervix, tubal ostia,hysteroscopic 
channels, anduterine vessels. An inner sheath can be used for inflow of media 
witha larger outer sheath, whichcan have perforations to allow for outflowof 
media in order to keep the visual field clear . Thedelivery system can be via 
closed or open system, with the former using fluid returned through a pump to 
areservoir and the latter allowing free flow of the media out through the cervix 
into a collection bag for volume monitoring. For clearer visibility, an optional 
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active suction can be placed at the outflow to clear debris from the field when 
needed.  
 Different kinds of deliverysystems are suited tothe various types of 
media. The simplest isasyringe that most oftenis used with the high-viscosity 
dextran 70. A hanging gravity-fed container that can be raisedor compressed 
with a cuff can be unreliable for pressures. Pumps are available that monitor 
pressure and volume for low-viscosity media. 
 
 
 
 
 
 
 
 
 
 
GASES : 
 Carbon dioxide    has   been   used   since     1920,  when  it   was   added    
by    Rubin   during   tubal   perflation . The   refractory   index   of   carbon   
dioxide   is  1.0, which   allows   for   excellent   clarity. Carbon dioxide   is  
primarilyemployed   for   diagnostic   hysteroscopy. Carbon  dioxide   is   
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rapidly   absorbed   and   easily cleared  from   the body  via   respirations;  it   
allows  a wider  field   of   view   at  lower magnification. A  smallscope   can   
accommodate   the   gas  because   the   gas  can  flow  through  narrow  
operative  channels, making   anesthesia   and   cervical   dilation   unnecessary. 
However,   carbon dioxide   does   require   an   insufflator   specific  for 
hysteroscopy  to  regulate  flow  and   limit   maximal  desired intrauterine   
pressure.  Note   that   laparoscopic  insufflatorsare  not safe.  
 Usually,   a   flow   rate   to   40-60 mL/min   at   a   maximum pressure   
of   100 mm Hg   is   accepted   as   safe. Higher   pressures  and    rates   can   
result   in   cardiac   arrhythmias   and   arrest . The advantages   of    carbon 
dioxide   are   its   relatively   low   toxicity profile,   rapid   absorption,   and   
lack   of   destruction   to   instruments. Its   disadvantages   are   the   inability   
to   clear   the   lens when   bleeding   occurs,   resulting   in   loss   of   a   clear   
visual  field and     limited   visualization,  and   the   risk   of    embolization  
with exposed    blood  vessels. 
FLUIDS : 
 The    advantage   of    fluid   over   gas   is   the   symmetric distention   
of   the   uterus   with   fluid,  as   well   as   its   capacity  to flush    blood,   
mucus,   bubbles,   and   small   tissue   fragments   more effectively   out   of   
the   visual   field. Both   low-viscosity   and   high-viscosity    fluid   media   
can   be   used   for distention.  
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Low-viscosity fluid  
 Two   types   of   electrolyte-containing   fluids   exist,   sodium   chloride  
(0.9% sodium chloride,  which  is  154 mEq/L    of   sodium   and   chloride)  
and   acetated Ringer   solution. These   solutions   can be usedfor diagnostic 
hysteroscopy as well as for limited operative procedures. Operative procedures 
using mechanical, laser, or bipolar energy are safe. Both options are readily 
available, and complex equipment is not needed.  Two major disadvantages are 
associated with these solutions. They are miscible withblood, obscuring 
visibility with bleeding and thus requiring larger volumes to clear the operative 
field, and they are excellent conductors, which precludes proceduresthat 
useelectrosurgery. Note that new equipmenthas been developed that allows for 
surgical procedures in the setting of these solutions,ie, VersaPoint, ERA sleeve, 
and the OPERA STAR system. The nonelectrolyte fluids consist of 5% 
mannitol, 3% sorbitol, and 1.5% glycine. These fluids do not conduct electrical 
current and allow for better visualization when bleeding occurs.  
 The common disadvantage of all of the nonelectrolyte media istheir risk 
of overload from intravascular absorption (particularly >2 L), which requires 
fluid monitoring during use. All of these fluids areisotonic solutions that can be 
applied for diagnostic as well as operative hysteroscopy. However, 5% mannitol 
can be used only with monopolaroperative procedures. It is broken down by the 
liver to glycogen and excreted through the kidney, with a half-life of 100 
minutes (Marlow, 1995).  
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If 5%mannitolis administered intravenously, it remains in theextracellular    
compartment. Whenintravasation occurs with this media, fluid and electrolyte 
imbalances can result in pulmonary edema, which can be treated with a diuretic. 
The 3% sorbitol is broken down bythe liverto fructose and glucose, which 
increases postoperative risks of hyponatremiaand hyperglycemia. 
Adilutionalhyponatremia also can occur with fluid overload   .Use   caution   
when   this   is   used in    a   patient    with   impaired   hepatic   function   
because   glycine   is metabolized   to   ammonia   and   serine . 
High-viscosity fluid : 
 The    only    high-viscosity   medium  available   is   dextran  70 or   
Hyskon,   which   is   32%  dextran   70  in   10%  dextrose  in  water. Dextran    
is    a   high–molecular    weight   substance   of   70,000 d. It  is   a   
nonelectrolytic, nonconductive   fluid   that   can   be   applied  in operative   and   
diagnostic  procedures. Because   of   its   high     viscosity,   dextran   70    is   
immiscible  with  blood   and  has  minimal leakage   through  the   cervix  and  
tubes, allowing  for   excellent visibility   during   surgical   procedures.  
 However,   avoid   more   than   500 mL   of   absorption  to prevent   
fluid   overload   because   it   is   a   volume  expander  with  a high   risk   of   
pulmonary   edema. With   each   100 mL   of   dextran 70 absorbed, the   
intravascular    volume   is   increased   by   800 mL. This medium has a large 
adverse effect profile, including allergic reactions and anaphylaxis, fluid 
overload, disseminated intravascular coagulopathy, and destruction of 
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instruments(which must be cleaned shortly after use because thesolution can 
stick to the equipment).  
INDICATIONS FOR HYSTEROSCOPY  : 
1. Evaluation of unexplained abnormal uterine bleeding in pre-menopausal or 
post-menopausal patients.  
2. Diagnosis and trans-cervical hysteroscopic removal of suspected sub mucous 
leiomyoma or endometrial polyp.  
3. Location and retrieval of ‘lost’ IUD or other foreign body  
4. Evaluation of primary and secondary infertility including confirmation of 
abnormal hysterogram 
5. Diagnosis and surgical treatment of intra-uterine adhesions.  
6. Exploration of endo-cervical canal, internal cervical os and uterine cavity in 
patients with repeated miscarriages.  
7.Diagnosis of uterine anomalies . 
8. Evaluation of patients with failed first-trimester elective abortions.  
9. Trans-cervical division of small uterine septae.  
10. Assessment of uterine wall defects following surgical procedure such as: 
myomectomy, caesarean section and hysterotomy.  
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      0 PedunculatedIntracavitary 
      1 <50% Intramural 
      2 >/=50% Intramural 
      3 Contacts endometrium; 100% Intramural 
      4 Intramural 
      5 Subserosal>/=50% Intramural 
      6 Subserosal<50% Intramural 
      7 SubserosalPedunculated 
      8 Other (specify e.g. Cervical, parasitic) 
  
Two numbers are listed separated with hyphen. By convention, 1
st
 
is relation with endometrium and 2
nd
 with serosa. 1 example is 
below- 
 2-5 Submucosal&subserosal, each with < 1/2 the diameter 
in the endometrial & peritoneal cavities. 
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CONTRA-INDICATIONS FOR HYSTEROSCOPY : 
ABSOLUTE:  
1. Recent or existing uterine infection: Cervical or uterine infection must be 
ruled out prior to hysteroscopy. Patients with recent uterine or adnexal 
infection should not undergo the procedure which could exacerbate an 
infection  
2. Pregnancy: Hysteroscopy should not be undertaken in pregnant patients 
who desire to continue pregnancy, unless the value of information gained 
outweighs the potential dangers of infection or pregnancy interruption. 
3.  Profuse uterine bleeding: In patients with excessive uterine bleeding 
hysteroscopy cannot be performed satisfactorily regardless of the 
distension medium used. 
4. . Cervical malignancy: Because of the possibility of spreading the disease 
due to cervical manipulation, patients with known carcinoma cervix 
should be excluded. 
RELATIVE: 
1. Adenocarcinoma of endometrium, when the operator is not      familiar 
with this disease 
2. Marked cervical stenosis 
3. Operator unfamiliarity with instrumentation and technique 
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COMPLICATIONS OF HYSTEROSCOPY 
 Adverse effects resulting fromdiagnostic hysteroscopy are few compared 
to thosefollowing its therapeutic use. Faulty technique and selection 
ofinappropriate patients    are most frequentcauses of untoward sequelae. 
1)TRAUMA : 
Cervical laceration can result from rough manipulation by holding the cervix 
with tenacula. 
Forceful dilatation provokes unnecessary bleeding. Uterine perforation and 
thermo intestinal accidentscan occur. 
2) INTRAVASATION : 
Endometrial tuberculosis, sub mucous tumors, hypo plastic uterus and proximal 
tubal obstructionarepredisposing factors to venous intravasation. The risk of 
pulmonary embolism is very minimal. 
3) INFECTION : 
Hysteroscopic procedure can exacerbate latent salpingitis. Post-
operativesalpingitis, peritonitis and febrile reactions can occur. 
4) MORTALITY : 
Due to faulty technique of co2 insufflation.It is a very rare complication . 
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TECHNIQUE OF HYSTEROSCOPY : 
 Under   suitable   anaesthesia, patient  is  put  in  lithotomy position. After 
catheterizing  the bladder, per-speculum and per-vaginal  examination  is  done. 
Then  hysteroscope  is  introduced  into  the  cervical  canal under vision. The 
cervical canal is examined and  thehysteroscope is introduced into the uterus. 
The tubal ostia are visualized. The endometrial pattern is studied. 
ANAESTHESIA : 
 Anaesthesiais  optional  .Generalanaesthesia, Paracervical block and 
Systemic analgesia are commonly used. 
1. Paracervical block: 
It isused for patients not requiring additional surgical intervention. 
Concomitant analgesiamay be required in some cases but often is not 
necessary. 
2. General anaesthesia: 
 It is themethod of choice when additional surgical procedures are planned 
such as laparoscopy . 
3. Systemic Analgesia: 
 It may be sufficient for diagnostic purposes when smaller instruments are 
used. This is particularly true in multiparous patients in whom cervical 
dilatation may not be necessary. 
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ENDOMETRIAL STUDY BY HYSTEROSCOPE: 
In describing different morphologies 5 well defined criteria are considered: 
1) The surface may be smooth (or) rough. 
2) The height is constant in normal cases and decreases as nearing the 
isthmus and ostia. 
3) The macroscopic details of the glandular opening. 
4) The endometrial vessels. 
5) Tubal ostia — the normal ostia are smooth and straight with some parallel 
mucosal folds. 
Proliferative Endometrium: 
¾ The surface is smooth and the colour is white or yellow. 
¾ Height of the endometrium is 2-5 mm. 
¾ Pores of endometrial glands are seen and are situated regularly 
¾ Superficial  vascularization  forms  are  relatively  poor  and  are seen  as  
interrupted  and  punctate  lines.  
¾ Tubal ostia are normal.  
Secretory Endometrium:  
¾ The  surface  is   smooth  or   slightly rough. The  colour  varies from  
yellow  to  orange .  
¾ Height  of  the  endometrium  is  5mm-7mm.  
¾ Superficial vessels have typical geometrical pattern mimicking a net.  
¾ Tubal ostia are normal.  
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Natural Atrophy:  
¾ Surface is smooth and appears as white or yellow.  
¾ Height  of  the endometrium  is  less  than 1mm.  
¾  Visible glandular  openings are  absent.  
¾ There  is  complete absence of  superficial vessels though deeper vessels  
of  stroma can  be  seen . 
¾ The  tubalostia  are  either completely obliterated or seen as  fibrous  
folds.  
Induced Atrophy:  
¾ The  surface   is  rough  and  the  colour  is ochre . 
¾ Height is 1mm-2mm.  
¾ Visible glandular pores are absent.  
¾ Superficial vessels are inadequate but deeper stromal vessels are seen. 
¾ Tubal ostia show characteristic atrophy.  
Hyperplasia (Simple), Adenomatous hyperplasia and Carcinoma In-Situ:  
¾ Through  micro  hysteroscopy  this  cannot  be  differentiated although  
the  history  varies.  
¾ The   surface  and  colour  are variable (white, yellow or even pink)  
¾ Theendometrial height  is  quite  uneven correlated with pseudopolypoid   
aspect and very thick.  
¾ Rich superficialvascularization   is observed with no specific pattern. The 
endoscopicexamination easily provokes hemorrhage.  
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¾ Some glandular orifices can be seen. They are no longer well delineated 
and the regular disposition has been lost.  
¾ Tubal ostia are normal.  
Cystic hyperplasia:  
¾ Surface endometrial height and tubalostia features are identical with 
hyperplasia.  
¾ Rich superficialvascularisationwith the appearance of network is 
observed, but thepattern is unequal in size.  
¾ Trapped in the meshes of the "net" are several transparent cysts, which of 
often attain a diameter of several mm. Some are filledwith a brown liquid 
suggestive of intra-cystic hemorrhage.  
 
Pseudo Decidualisation:  
¾ The surface is rough.  
¾ Height ofthe endometrium is variable and has pseudo polypoidal 
appearance.  
¾ Rich congestivevascularization  is noted as seen in secretory phase.  
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¾ Visible glandular pores are absent.  
¾ Tubal ostia are normal.  
Polyps, Myomas and Carcinoma:  
¾ Benign endometrial polyps are seen as smooth discrete, shiny& vascular.  
¾ Sub mucous fibroids appearsmooth andpaler than the rest of the 
endometrium. 
 
SUBMUCOUS MYOMA 
¾ Endometrial carcinoma appearsas irregular lesion, vascularization   with 
surface ulceration and bleeding.  
Cervix:  
 
CERVICAL CANAL 
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¾ Cervical canal is seen as circular or oval with a smaller diameterantero 
posteriorly. 
¾  It has a smooth mucous membrane with a whitish appearance different 
from the lining of the uterus.  
¾ Endocervical arborvitae is seen with high magnification  
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MATERIALS AND METHODS 
SOURCE OF DATA:  
 The     present   study “A   CLINICAL  STUDY  OF   DIAGNOSTIC   
HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING AND ITS 
HISTOPATHOLOGICAL CORRELATION” is a prospective study, which has 
been carried out in the Department of Obstetrics and   Gynecology, Tirunelveli 
medical  college hospital, Tirunelveli , Tamilnadu.  
 The material for the present study was collected from patients who 
attended and were admitted in department of Obstetrics and Gynecology with 
Abnormal Uterine Bleeding. 50 cases of AUB were taken up for the study. All 
the patients in this study underwent   hysteroscopy   followed byDilatation and 
Curettage and the curettings were sent for Histopathology analysis.  
 The period of the study was from January 2011to October 2011 .The 
results of Hysteroscopy and Endometrial Histopathology were studied and 
analyzed. The analyzed data was compared with other series in literatureand 
discussed. Amaster chart dealing with all aspects has been designed and 
presented. All patients were well informed about the study in all aspects and 
informed written consent was obtained.  
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METHOD OF COLLECTION OF DATA:  
Inclusion criteria:  
1. Patientwith age between 20-60 yrs with Abnormal Uterine bleeding.  
2. Multiparous and nulliparous women. 
3. Patients who do  not require any emergency management . 
Exclusion criteria:  
1. Patients with severe anemia due to menorrhagia were excluded since they 
required immediate intensive care.  
2. Patients with profuse bleeding.  
3. Cases with large or multiple fibroids.  
4. Infection in the genital tract.  
5. Malignancies of  the genital tract 
 Caseswere selected by diagnosis on History, General Examination, 
Abdomen and Pelvic Examination and Routine investigations. Proforma 
specially made for the study was used. Patients were advised to have alight 
dinner before 10pm on the night prior to hysteroscopy.Bowel preparation and 
pre operative antibiotics were given.  
Laboratory investigations: 
 Blood grouping and typing, BT, CT,   
Blood urea, Serum creatinine, RBS, ECG, HIV, HBsAg. 
Ultrasonography . 
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INTERVENTIONS INCLUDED:  
1. Anaesthesia: In this study, hysteroscopy was performed under IV 
anaesthesia.  
                 Drugs used: Ketamine: 2mg/Kg body wt,Midazolam ,Pentazocine. 
                Diazepam: 10mg and Atropine: 0.6 mg  
2. Hysteroscopy:  
Hysteroscope:  
              This   instrument  is  a  modified  cystoscope  consisting  of   a stainless  
steel  sheath  equipped  with  stop  cock, controlled  channels for  distension  
medium  and  the  passage  of   ancillary  instruments. An obturator  to   
facilitate  introduction  of   the   sheath is a feature of the hysteroscope. 
Telescope  used  was  of   4mm  30  degrees  fore-oblique  lens  with  a  5mm 
sheath. Illumination provided  by  a  standard  150W  bulb  and  is  transmitted  
by  a  fibre  optic  cable.  
 Instruments:  
¾ Speculum, Vulsellum, Sponge holding forceps  
¾ D&C set with Dilators  
¾ Syringes and needles  
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Distension medium used was Normal Saline (0.9%)  
Procedure:  
 Under anaesthesia, aftercatheterising the bladder, a bimanual pelvic 
examination was done. After introducingSim’sspeculum, the anterior lipofthe 
cervix was held  with vulsellum. After measuring the length of the uterine 
cavity, the internaloswas dilated ,the hysteroscope was introduced into the 
cervical canal under vision. The uterine cavity was distended 0.9% normal 
saline and  examined. 
The following points were noted:  
1. The nature of surface and colour of endometrium  
2. The glandular openings.  
3. The vascular pattern.  
4. The tubal ostia.  
5. Any other abnormalities.  
               Patients  with  normal  uterine  cavities  without  any questionable  
areas  were  labeled  as “NEGATIVE  HYSTEROSCOPIC VIEW” when  the  
following  3  criteria  were  met:  
1. Good visualization of entire uterine cavity  
2. No structural abnormalities in the cavity.  
3. A  uniformly  thin, homogenous  appearing  endometrium without  
variation  in  thickness.  
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3. Dilatation and Curettage:  
        Under   the  sameanaesthesia,  curettage   was   done   with   a   sharp   
curette   and   the  endometrial curettings   were   sent   for histo-pathological 
examination.  
POST-OPERATIVE:  
        Post  operatively  vitals  were  monitored ,oral fluids  started  after  four  
hours    and  were  given   broad   spectrum   antibiotic. Most   of   the  patients  
were discharged   on   the   next   day.  
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CLINICAL  PRESENTATION 
TABLE 5 
 
 
Majority   of   the   patients, 22 (44%) presented  with  Menorrhagia. The  
second commonest group had  Post-menopausal Bleeding, 13 cases (26%) 
.There were 9 cases (18%) with  Polymenorrhagia and  6 patients  (12%)  with   
Metrorrhagia . 
 
44%
18%
12%
26%
CLINICAL  
PRESENTATION 
NO OF PATIENTS PERCENTAGE 
menorrhagia 22 44% 
polymenorrhoea 9 18% 
metorrhagia 6 12% 
Postmenopausal  bleeding 13 26% 
  
TABL
Age / C
menor
polym
metorr
Postm
bleedin
in the
presen
0
2
4
6
8
10
12
AGE D
E - 6 
ondition
rhagia 
enorrhoea
hagia 
enopausal
g 
Of the 50
 age grou
tation in t
 
 
20‐29
ISTRIB
  20-29
1 
 2 
0 
  0 
 patients,p
p of 40
he age gro
30‐39
UTION A
 30
olymeno
-49 years
up of 30-
40
60
ND CON
-39 
10 
4 
3 
0 
 
rrhoea wa
 and me
39 years. 
‐49
DITION
40-49 
11 
3 
3 
3 
s the com
norrhagia
  
50‐60
 EVALU
50-60
0 
0 
0 
10 
mon clin
 was the
MEN
POLY
MET
PMB
ATED  
 Tot
of P
ical prese
 most co
ORRHAGIA
MENORRHO
ORRHAGIA
al No. 
atients 
22 
9 
6 
13 
 
ntation 
mmon 
EA
  
TABL
E .POL
SUBM
MYOM
E. HY
E. ATR
ENDO
NORM
 
Abnor
patient
The m
follow
of Sub
FINDING
E - 7 
FINDING
YP 
UCOUS 
A 
PERPLAS
OPHY 
METRIT
AL 
mal  findi
s (50%), 
ost comm
ed by End
mucousM
‐5%
0%
5%
10%
15%
20%
25%
30%
35%
0
S  AT  H
S 
IA 
IS 
ngs  were
no abno
on abnorm
ometrial 
yomas, 4
10%
1
YSTERO
NO O
  seen in 
rmality w
ality  w
Polyps (5
 cases (8%
10%
2
61
SCOPY
F PATIE
5 
5 
10 
4 
1 
25 
25 patient
as detect
as Endom
 cases, 10
) of Endo
 
20%
3
 
NTS 
s (50%), 
ed (nega
etrial Hyp
%). Ther
metrial A
8%
2
4 5
PER
while in t
tive hyste
erplasia 
e were als
trophy . 
%
30%
6
CENTAG
10% 
10% 
20% 
8% 
2% 
50 % 
he remain
roscopic 
(10 cases,
o 5 cases
7
E 
 
ing 25 
view).  
 20%), 
 (10%) 
  
TABL
NO
EN
HY
SUB
E . 
E . 
EN
IRR
 
‐5%
0%
5%
10%
15%
20%
25%
30%
35%
E - 8 
FIN
RMAL 
DOMETR
PERPLA
MUCOU
ATROPH
POLYP  
DOMETR
EGULAR
0
FINDI
DINGS 
IAL 
SIA 
S MYOM
Y  
ITIS  
  SHEDD
30%
2
1
NGS  AT
A 
ING 
2%
2 3
62
  HISTO
NO 
PATIE
30
11
0
5
2
0
2
0%
10
4
PATHOL
OF 
NTS 
 
 
 
 
 
 
 
%
4
5
OGY 
PERC
%
6
ENTAGE
60% 
22% 
0% 
10% 
4% 
0% 
4% 
PERCENT
 
 
AGE
   63
 Of  the 30 normal cases (60%) reported, 8 cases had abnormal findings. 
The diagnosis  of  3  cases  of Endometrial Polyps and 5 cases of 
SubmucousMyoma was missed by Endometrial Histopathology.  
 Among the 11 cases of endometrial hyperplasia one case was associated 
with submucousmyoma which was missed by endometrial histopathology 
.Histopathology  correctly  diagnosed all the  other cases of endometrial 
hyperplasia  and irregular shedding endometrium .  
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VALIDITY  OF  HYSTEROSCOPY 
TABLE - 9 
HYSTEROSCOPY DISEASE  PRESENT DISEASE  ABSENT 
POSITIVE 24 (a) 1 (b) 
NEGATIVE 2(c) 23 (d ) 
(a) - true positive 
(b) – false positive 
(c) – false negative 
(d) – true negative 
Θ Sensitivity: a /a+c x 100 = 24/26 x 100 = 92.30%  
Θ Specificity: d / b+dx 100 = 23/24 x 100 = 95.8% 
Θ Positive Predictive Value: a / a+b x 100 = 24/25 x 100 = 96 %  
Θ Negative Predictive Value: d / c+d x 100 = 23/25 x 100 = 92 %  
Θ False Positive Rate: b / b+d x 100 = 1/24 x 100 = 4.16 %  
Θ False Negative rate: c / a+c x 100 = 2/26 x 100 = 7.69 %  
Θ Concordance (Accuracy): a+d / a+b+c+d x 100 = 47/50 x 100 = 94 %  
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VALIDITY  OF  DILATATION  AND  CURETTAGE 
TABLE - 10 
DILATATION AND 
CURETTAGE 
 
DISEASE PRESENT 
 
DISEASE  ABSENT 
POSITIVE 18(a) 1(b) 
NEGATIVE 8(c) 23(d) 
(a) - true positive 
(b) – false positive 
(c) – false negative 
(d) – true negative 
Θ Sensitivity: a /a+c x 100 = 18/26 x 100 = 69.2%  
Θ Specificity: d / b+d x 100 = 23/24 x 100 = 95.8 %  
Θ Positive Predictive Value: a / a+b x 100 = 18/19 x 100 = 94.7% 
Θ Negative Predictive Value: d /c+d x 100 = 23/31 x 100 = 74.19 %  
Θ False Positive Rate: b / b+d x 100 = 1/24 x 100 = 4.16 % 
Θ False Negative rate: c / a+c x 100 = 8/26 x 100 = 30.76 % 
Θ Concordance (Accuracy): a+d / a+b+c+d x 100 = 41/50 x 100 = 82%  
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COMPARISON  OF  VALIDITIES 
TABLE - 11 
  
  HYSTEROSCOPY 
 
HISTOPATHOLOGY
 
SENSITIVITY 
 
92.3% 
 
69.2% 
 
SPECIFICITY 
 
95.8% 
 
95.8% 
 
PPV 
 
96% 
 
94.7% 
 
NPV 
 
92% 
 
74.19% 
 
ACCURACY 
 
94% 
 
82% 
 
                 Both hysteroscopy and curettage were accurate when an abnormality 
was diagnosed, giving a Specificity of 95.8%. and Positive Predictive Value 
(PPV) of 96%  and 94.7% .  
 The ability to diagnose a lesion (Sensitivity) was more with Hysteroscopy 
in comparison to Curettage (92.3% v/s 69.2%), while a negative diagnosis was 
less wrongly made with Hysteroscopy (False Negative Ratio: 7.69% v/s 
30.76%) . 
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FINAL DIAGNOSIS AFTER HYSTEROSCOPY AND 
HISTOPATHOLOGY 
TABLE - 12 
Diagnosis Menorrhagia Polymenorrhoea Metrorrhagia PMB 
Total 
No. %  
Polyp  4  0  0  1  5 10%
Submucousmyoma 2  3  0  0   5 10% 
Hyperplasia  4  0  3 3 10  20% 
Endometritis 0 0  0  0  0  0% 
E. Atrophy  0  0  0  4  4  8 % 
Irregular shedding 2 0 0 0 2 4% 
Normal 10 6 3 5 24 48%
Total  22  9  6  13  50  100 
 
Of the 50 patients tested 24 patients had normal findings, 26 patients had 
abnormal findings , out of which 5 (10%) cases had endometrial 
polyp,5(10%)had sub mucous myoma ,10 (20%) cases had endometrial 
hyperplasia , (8%) had endometrial atrophy,and 2(4%) had irregular shedding 
pattern of endometrium. 
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DISCUSSION 
 In the present study “A CLINICAL STUDY OF DIAGNOSTIC 
HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING AND ITS 
HISTOPATHOLOGICAL CORRELATION”, diagnostic hysteroscopy was 
performed in 50 consecutive cases of AUB and its correlation  
withhistopathological findings were sought.  
 The age group in this study was between 20-60 years and maximum 
incidence was between 40-49yrs. Panda
33 
found that maximum age incidence 
was between 35-45yrs in range between 25-70yrs. In Gianninoto’s
39 
series, age 
range was 38-80yrs and commonest incidence was between 30-45yrs. 
Trotsenburg
34 
reported maximum age incidence between 41-50yrs.  
 The commonest presenting complaint in this series was menorrhagia 
(44%) followed by Postmenopausal Bleeding (26%) and Polymenorrhoea 
(18%). Panda’s
33 
series had 60% cases of menorrhagia followed by 
Polymenorrhagia and Metrorrhagia. In this study, abnormal findings on 
hysteroscopy were found in 26 patients (52%) while in the remaining 24 
patients (48%), no abnormality was detected.  
 The following table compares normal and abnormal findings in 
hysteroscopy in various series:  
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Normal and Abnormal findings at Hysteroscopy in various series. 
TABLE – 13 
Sl. No.  Author (Year)  No. of Cases  Normal (%)  Abnormal 
(%)  
1  Wamsteker (1984)  199  41.5  58.5  
2  Gimpelson&Rappold 
(1988)  
276  60  40  
3  Loffer (1989)  91  48.66  51.44  
4  Sheth (1990) 51  44  56  
5  Parasnis (1992)  96  73.95  26.05  
6  Neumann (1994)  85  55.2  44.8  
7  Panda (1999)  66  46.6  53.4  
8  Trotsenburg (2000) 819  66  34  
9  Garuti (2001)  1500  61.8  38.2  
10  Gianninoto (2003)  512  25  75  
11  de Wit AC (2003)  1045  54.2  45.8  
12  Present Series  50  48 52 
 
 Of the 26 cases with abnormal findings on hysteroscopy, commonest seen 
was Endometrial hyperplasia (10 cases, 20%), followed by Endometrial polyps 
(5 cases, 10%) and SubmucousMyoma (5 cases, 10%). Pandafound endometrial 
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hyperplasia in 28.3%, Wamstekerfound endometrial polyp in 19%, endometrial 
hyperplasia in 12.2% and submucousmyoma in 7.8%, Trotsenburgobserved 
myomas and polyps in 14% and deLewitreported myomas in 21% and polyps in 
14.4%.  
 Hysteroscopy diagnosed all cases of endometrial hyperplasia, polyps and 
myomas with a specificity of 100%. Shethreported 81.8 % accuracy in diagnosis 
of polyps and myomas, while Garutireported 95.4% specificity in diagnosis of 
polyps.  
 In the present study,   among the 50 patients tested , 26 patients actually 
had some pathology , of  which 24 were  accurately  detected  by hysteroscopy 
missed two cases of irregular shedding  endometrium and  hysteroscopy made a 
false positive diagnosis of endometritis in 1 case  .These  two cases of  irregular 
shedding endometrium was accurately reported by histopathology .  
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Comparison of Accuracy of Hysteroscopy findings 
TABLE – 14 
Author  Accuracy  Misinterpretation  
Baggish (1979)  87.5  12.5  
Barbot (1980) 
20
 84  16  
Sheth (1990) 
26
 82  18  
Parasnis (1992) 
27
 92  8  
Panda (1999) 
33
 92.69  7.31  
Present Series  94  6  
                            P VALUE : 0.00478 ( statistically significant ) 
 Hysteroscopy  accurately detected endometrial polyp,submucous fibroid  
and all cases of endometrial hyperplasia .A study conducted by European 
society of Human reproduction & embryology 2002 concludes that 
hysteroscopy with endometrial biopsy is the “Gold standard”investigation for 
AUB57. 
 A Cochrane database systems review 2007 ,compares Hysteroscopy and 
Dilatation and Curettage (D&C) showed D&C is obsolete because it is a blind 
methodwith a complication rate of 4 to 6.% and low sensitivity for local and 
pendunculatedintracavitaryleisions. It requires hospital stay and general 
anaesthesia. Withhysteroscopic visualization, organic leisions are not missed 
and directed biopsy can beperformed (Pellicano 2003). Astudy conducted at 
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University of Winconsin, Madison showedhysteroscope with biopsy allows 
visualization of endometrial cavity and is regarded asgold standard for 
endometrial assessment 58. 
Comparison of Validity factors of Hysteroscopy 
TABLE – 15 
Author  Sensitivity  Specificity  
Loverro (1996)  98  95  
Garuti(2001)  94.2  88.8  
Loffer(1989)  98  100  
Parasnis (1992)  92  100  
Panda (1999)  92.5  78.78  
Present Series  92.3 95.8 
 
Statistical analysis of sensitivity and specificity of hysteroscopy;  
 There is no significant difference between sensitivity and specificity 
obtained in this study and that obtained by various other authors. This confirms 
the validity of hysteroscopy done in the present study. 
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Comparison of Validity factors of Dilatation and Curettage 
TABLE – 16 
Author  Sensitivity  Specificity  
Loverro(1996)  79.2  95  
Garuti(2001)  78  94  
Loffer(1989)  65  100  
Parasnis (1992)  76  100  
Present Series  69.2 95.8 
 
 A comparison of sensitivity and specificity of D&C obtained in the 
present study with those obtained by other authors shows no significant 
difference between the obtained values.  
 In the present series , of  the 50 patients tested , 26 actually had pathology 
, out of which , 18 was accurately diagnosed by histopathology . Among the 8 
cases missed 5 had submucousmyoma and 3 had endometrial polyp . 
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COMPARISON OF SENSITIVITY AND PREDICTIVE VALUES : 
 In the  present  series  hysteroscopy  showed a sensitivity of 92.3% ,were 
as curettage was 69.2% sensitive ,with a P VALUE OF O.OOOO2  ,which is 
statistically significant .Hence hysteroscopy is 23% more sensitive than 
curettage  and this is not due to chance. While  comparing  the negative 
predictive values ,hysteroscopy showed 92% and curettage showed 74.19% , 
with a P VALUE OF 0.00036 , which is statistically significant . 
In the present study, the results of hysteroscopy and dilatation and curettage 
were in agreement in 76% patients, hysteroscopy revealed moreinformation 
than curettage in 18 % patients and curettage revealed more information than 
hysteroscopy in 4% patients .This is comparable to other similar studies which 
shows that Panoramic Hysteroscopy is better than Curettage in the evaluation of 
abnormal uterine bleeding.  
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SUMMARY 
 50 Patients who presented with Abnormal Uterine Bleeding underwent 
panoramic hysteroscopy and subsequent Dilatation and Curettage.  
 Curetted endometrium was sent for histopathological examination.  
 Age group of the patients ranged from 20-60yrs and most common age 
group was 40-49yrs (40%).  
 Most of the patients (40%) had symptoms for more than 1 year and most 
common presenting symptom was Menorrhagia (44%) and 
Postmenopausal bleeding (26%).  
 Hysteroscopy reported 25 pts (50%) as negative view and 25 pts (50%) as 
abnormal view. But actually 24 patients were normal ,and 26 patients had 
some pathology .Hysteroscopy missed two cases of irregular shedding 
endometrium, 
 Endometrial hyperplasia (20%) was the most common abnormality, 
followed by endometrial polyp (14%).  
 The Sensitivity, Specificity, NPV and PPV for Hysteroscopy was 92.3%, 
95.8%, 92% and 96% respectively and for D&C was 69.2%, 95.8%, 
74.19% and 94.7% respectively.  
 The most consistent finding has been the detection of endometrial 
hyperplasia, endometrial polyp and submucousmyomas with 100% 
accuracy using hysteroscopy. 
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CONCLUSION 
 This study confirms that hysteroscopy is superior to curettage in 
evaluating patients with abnormal uterine bleeding.  
 Hysteroscopy  is  a  safe, reliable and quick procedure in the diagnosis of 
cases with  abnormal uterine bleeding with high sensitivity, specificity and 
negative predictive value .  
 In  this  study  hysteroscopy  correlated  more  with  histopathologic  
findings and also identified associated pathology like polyps 
andsubmucousfibroids.It is both accurate and feasible when compared to  
histopathology  in  identifyingintracavitary abnormalities . Hence hysteroscopy  
forms  an  efficient  investigative   tool  in diagnosing the endometrial  
pathology  in cases of abnormal uterine bleeding . The technique  may  be  
learned  with  relative  ease and it should become part of armamentarium of 
every gynaecologist . 
 
 
 
 
                                      
ABBREVIATIONS 
 
AUB : Abnormal Uterine Bleeding  
BT : Bleeding time  
CT : Clotting time  
CO2 : Carbon Dioxide gas  
CNS : Central Nervous System  
D&C : Dilatation and Curettage  
DUB : Dysfunctional Uterine Bleeding  
ECG : Electrocardiogram  
HRT : Hormone Replacement Therapy  
IUD : Intra Uterine Device  
NPV : Negative Predictive Value  
PMB : Post Menopausal Bleeding  
PPV : Positive Predictive Value  
Pts : Patients  
RBS : Random Blood Sugar  
Yrs : Years 
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ANNEXURE 1  
 
HYSTEROSCOPIC PROFORMA FORM 
Name : 
 
 Age : 
  
IP NO :  
 
Education : 
 
 Occupation : 
  
D.O.A :  
 
S. E. Status : 
  
D.O.OP : 
 
Address :  
 
D.O.D :  
 
Complaints:  
      
       
   
Past Contraception :  
No of children : 
 
 L.C.B : 
  
Sterilization done/not: 
 
 L.M.P : 
  
Past history: 
  
H/o D&C 
  
Tubal ligation/ IUCD 
  
Obstetric history:  
 
Family history: 
 h/o bleeding disorders  
Drug history: 
        Hormones for DUB  
GENERAL EXAMINATION: 
  
Vital data PR: BP:  
 
Abdominal Examination: 
  
Bimanual Pelvic Examination: 
  
Uterus-size Shape: 
  
Consistency: Surface: 
  
Contour: Mobility:  
Adnexae: 
 
 
Speculum Examination:  
P/V Examination:  
 
Investigations: 
  
Haemogram –  
Urine – Alb, Sugar, Micro :  
 
Blood grouping Rh typing :  
 
Urine C/S : 
  
Thyroid function tests :  
 
X– Ray chest :  
                                      
H/o diabetes 
  
H/o hormone therapy 
  
H/o bleeding disorders  
 
H/o anticoagulant drugs  
 
E.C.G :  
U.S.G :  
Other investigations :  
Clinical diagnosis:  
Hysteroscopy findings:  
Cervix :  
Endocervix :  
Isthmus :  
Endometrial cavity :  
Endometrium :  
Right cornu :  
Right tubal ostium :  
Left cornu :  
Left tubal ostium : 
 
  
                                      
  
ANNEXURE 2  
SAMPLE OF INFORMED CONSENT FORM  
Title of the project: A CLINICAL STUDY OF DIAGNOSTIC 
HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING AND ITS 
HISTOPATHOLOGICAL CORRELATION.  
Purpose of research:  
I have been informed that this study will evaluate the accuracy of hysteroscopy 
in the diagnosis of Abnormal Uterine Bleeding. This study will help 
Gynecologists in accurate diagnosis of cases of Abnormal Uterine Bleeding.  
Procedure:  
I understand that I will be undergoing this procedure for the evaluation of my 
condition. I am aware that immediately after completion of the procedure, I will 
be undergoing Dilatation and Curettage and the sample obtained from the 
curettage will be sent for histopathological analysis. I am also aware that I will 
be carefully observed and I will be asked a series of questions by the researcher 
pertaining to my condition. I will not be asked to make any special trips to the 
hospital for follow-up.  
Risks and Discomforts:  
I understand that the procedure of this study is not expected to aggravate any of 
the effects which are associated with the usual course of the treatment.  
                                      
Benefits:  
I understand that my participation in this study will have no direct benefits to 
me other than the potential benefit of the treatment. The major potential benefit 
is the accurate and the early diagnosis of my condition.  
Alternatives:  
I understand that the procedure which I am undergoing is the standard method 
of treating my problem.  
Confidentiality:  
I understand that the medical information produced in this study will become 
part of hospital records and will be subject to confidentiality record and privacy 
regulation of tirunelveli Medical College Hospital. Information of a sensitive 
nature will not be a part of the medical record, but will be stored in the 
investigator’s research file and identified only by code number; the code key 
connecting name to numbers will be kept in a separate secure location.  
If the data are used for publication in the medical literature or for teaching 
purposes, no names will be used and other identifiers such as photographs and 
audio and video tapes will be used only with my special written permission. I 
understand that I may see the photographs and the video tapes and hear the 
audio tapes before giving this permission.  
I understand that the relevant designated authority and industrial sponsor are 
permitted to have access to my medical records and to the data produced by the 
study for audit purpose. However they are required to maintain confidentiality.  
                                      
Request for more information:  
I understand that I may ask questions about the study at any time and 
understand that I will be informed of any significant new finding discovered 
during the course of the study which might influence my continued 
participation.  
If during the study or later I wish to discuss my participation in or concerns 
regarding this study with a person not directly involved, I am aware that the 
other staff members are available to talk to me.  
A copy of this consent form will be given to me to keep for careful reading.  
Refusal or withdrawal of participation:  
I understand that my participation is voluntary and that I may refuse to 
participate or withdraw consent and discontinue participation in the study at any 
time without prejudice to my present or future care in the hospital and also 
understand that the researcher may terminate my participation in the study if at 
any time she feels the need and explain me the reason to do so and help to 
arrange for my further appropriate treatment.  
I confirm that the researcher has explained to me the purpose of research, the 
study that I will undergo and the possible risks and discomforts as well as 
benefits that I may experience. I have read and I understand this consent form. 
Therefore I agree to give my consent to participate as a subject in this research 
project.  
                                      
I have been explained in detail all the aspects of the procedure and 
consequences in my own vernacular language.  
 
Participant:        Witness:  
 
Date:         Date:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      
KEY TO MASTER CHART  
 
1. Sl. no. : Serial number  
2. Name :  
3. Age (years) :  
4. IP NO : In Patient Number  
5  D.O.H : Date Of Hysteroscopy  
6. Proliferative : Proliferative endometrium  
7. Secretory : Secretory endometrium  
8. E. hyperplasia : Endometrial hyperplasia  
9. E. polyp : Endometrial polyp  
10. Atrophic : Atrophic endometrium  
11. PMB : Post menopausal bleeding  
12. E. atrophy : Endometrial atrophy.  
 
 
S. No Name Age IP No. Date of 
hysteroscopy
Clinical 
Presentation
Hysteroscopy findings Histopathology findings
1 Mazhai Azhagu 43 56261 3/1/2011 Menorrhagia Proliferative Proliferative 
2 Mariammal 41 2744 3/1/2011 Menorrhagia Proliferative Proliferative 
3 Parvathi 44 3096 10/1/2011 Polymenorrhoea Proliferative Proliferative 
4 Packiarathi 48 3936 17/1/2011 Menorrhagia E. Polyp Proliferative 
5 Backialakshmi 48 34517 17/1/2011 PMB Proliferative Proliferative 
6 Balarohini 40 34512 24/1/2011 Metorrhagia Secretory Secretory
7 Bhagavathi 40 27161 24/1/2011 Metorrhagia E. Hyperplasia Cystoglandular Hyperplasia
8 Jainambu 38 58331 7/2/2011 Menorrhagia Secretory Secretory
9 Thangathai 50 56085 14/2/2011 PMB Proliferative Proliferative 
10 Mari 52 29398 22/3/2011 PMB E. Hyperplasia Simple hyperplasia
11 Krishnammal 28 56764 22/3/2011 Polymenorrhoea Submucous myoma Secretory
12 Esaiarasi 36 58315 4/4/2011 Menorrhagia E. Polyp Proliferative 
13 Solai Ammal 40 5722 4/4/2011 Menorrhagia Submucous myoma Secretory
14 Vellathai 60 3750 11/4/2011 PMB secretory Secretory
15 Sulthan Beevi 32 57141 11/4/2011 Menorrhagia Secretory Secretory
16 Kannimariyal 48 36021 13/5/2011 PMB atrophic Atrophic
17 Rajabnisha 38 52661 13/5/2011 Polymenorrhoea Proliferative Proliferative 
18 Kaliammal 50 36041 13/5/2011 PMB E. Hyperplasia Adenomatous hyperplasia
19 Thangam 41 43359 19/5/2011 Menorrhagia Secretory irregular shedding
20 Valliammal 41 15857 26/5/2011 Menorrhagia Leiomyomatous Polyp Benign Polyp
21 Ramalakshmi 37 13763 26/5/2011 Menorrhagia E. Hyperplasia Simple hyperplasia
22 Kaliammal 50 36041 26/5/2011 PMB E. atrophy Atrophic
23 Mary 41 40052 13/6/2011 Polymenorrhoea Secretory Secretory
24 Esakkiammal 45 57097 13/6/2011 Metorrhagia E. Hyperplasia Adenomatous hyperplasia
25 Gomathi 59 46901 20/6/2011 PMB E. Polyp Proliferative 
26 Kaniammal 40 12111 20/6/2011 Menorrhagia Secretory Secretory
S. No Name Age IP No. Date of 
hysteroscopy
Clinical 
Presentation
Hysteroscopy findings Histopathology findings
27 Malavika 34 58186 28/6/2011 Polymenorrhoea Secretory Secretory
28 Seethalamshmi 45 14159 30/6/2011 Menorrhagia Simple cystic hyperplasia Simple hyperplasia
29 Lakshmi 35 31429 11/7/2011 Metorrhagia Proliferative Proliferative 
30 Kanka 47 19640 12/7/2011 Menorrhagia E. Polyp Benign Polyp
31 Velammal 50 28416 12/7/2011 PMB Endometritis Secretory
32 Balammal 33 42402 14/7/2011 Menorrhagia Secretory Secretory
33 Meena 50 7883 14/7/2011 PMB E. Atrophy Atrophic
34 Ponmari 34 12599 16/7/2011 Menorrhagia proliferative proliferative 
35 Kani 33 38223 18/7/2011 Metorrhagia Secretory Secretory
36 Ganapathiammal 60 10931 18/7/2011 PMB E. Atrophy Atrophic
37 Sakthiselvi 40 9479 26/7/2011 Menorrhagia Secretory atrophic
38 Sornam 37 58182 26/7/2011 Polymenorrhoea Submucous myoma Secretory
39 Prema 36 21246 30/8/2011 Metorrhagia E. Hyperplasia Cystoglandular Hyperplasia
40 Mariammal 45 34888 5/9/2011 Menorrhagia Proliferative Proliferative 
41 Muruganandhi 47 58304 5/9/2011 Polymenorrhoea Proliferative Proliferative 
42 Pooncholai 48 12806 12/9/2011 PMB E. Hyperplasia Adenomatous hyperplasia
43 Selvi 36 34939 19/9/2011 Menorrhagia Secretory Secretory
44 Marikani 32 46894 26/9/2011 Menorrhagia E. Hyperplasia Simple hyperplasia
45 Devaki 24 56986 26/9/2011 Menorrhagia Simple cystic hyperplasia Simple hyperplasia
46 Vasantha 29 21246 26/9/2011 Polymenorrhoea Submucous myoma Secretory
47 Dhamayanthi 30 39861 10/10/2011 Menorrhagia Submucous myoma Simple hyperplasia
48 Subbulakshmi 36 40455 10/10/2011 Menorrhagia secretory irregular shedding 
49 Saraswathi 50 44700 24/10/2011 PMB Proliferative Proliferative 
50 Chellathai 34 42362 24/10/2011 Polymenorrhoea Proliferative Proliferative 
